Healthcare Sales & Marketing Network News: peginterferon

Searching News Database: peginterferon

HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch

HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Aug 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Jun 2019
Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Apr 2017
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 11 Apr 2014
Gilead’s Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Biopharmaceuticals

HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals

HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead’s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Nov 2013
Vertex Sells INCIVO(R) Product Royalty Rights for $152 Million
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 21 May 2013
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY(TM) (Peginterferon Beta-1a) in Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 4 Sep 2012
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals

HSMN NewsFeed - 10 Aug 2010
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 25 Apr 2009
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 20 Apr 2009
Newly Published Study Shows That Re-Treatment With Pegasys(R) (Peginterferon Alfa-2a) Provides Hepatitis C Patients With a Second Chance for a Cure
Biopharmaceuticals

HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Mar 2009
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 17 Feb 2009
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 4 Dec 2008
European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jun 2008
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals

HSMN NewsFeed - 26 Nov 2007
Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals

HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals

HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Aug 2007
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Biopharmaceuticals

HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Jun 2007
Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon(R)
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2007
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2007
PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 21 May 2007
Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Mar 2007
Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2007
Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 19 Dec 2006
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 31 Oct 2006
Human Genome Sciences Reports Positive Interim Results of Phase 2 Trials of Albuferon(TM) With Ribavirin in Patients With Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Customizing Treatment with PEGASYS(R) May Improve Chances for Success in Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients in Early Trial
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals

HSMN NewsFeed - 16 Oct 2006
Human Genome Sciences Reports Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon(TM) with Ribavirin in Treatment-Naive Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 13 Oct 2006
Roche Advances Oral Polymerase Inhibitor into Phase II Study in Patients with Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 12 Sep 2006
Valeant Pharmaceuticals Reports VISER2 Results for Viramidine(R)
Biopharmaceuticals

HSMN NewsFeed - 30 Jun 2006
Jonathan R. Spicehandler, M.D. Retires From Schering-Plough
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 23 May 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
Biopharmaceuticals

Return to NewsFeed

Additional items found! 66

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 66 additional stories matching:
peginterferon
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.